NYSE:Acceleron Pharma Inc.

График котировок Acceleron Pharma Inc.


Добавить в список сравнения Добавить в список сравнения
Добавить в список отслеживания Добавить в список отслеживания
Добавить в портфель Добавить в портфель

Основные параметры

P/S 71.56
P/BV 8.44
EV/EBITDA -50.57
EBITDA -0.13
Цена ао 125.88

Инсайдерская торговля

Дата сделки Дата раскрытия Инсайдер Тип Цена Объем Количество Доля до, % Доля после, % Документ
11.12.2020 11.12.2020 MCLAUGHLIN KEVIN F
SVP, CFO and Treasurer
Продажа 125 387 500.00 3100 0 -0.01 ссылка
09.12.2020 11.12.2020 MCLAUGHLIN KEVIN F
SVP, CFO and Treasurer
Продажа 125.03 484 116.00 3872 0 -0.01 ссылка
10.12.2020 11.12.2020 MCLAUGHLIN KEVIN F
SVP, CFO and Treasurer
Продажа 125.12 62 560.00 500 0 0 ссылка

Основные владельцы

Institutions Объем Доля, %
Hennion & Walsh, Inc 200 0
Foresite Capital Management III, LLC 108630 0.18
Peroni Portfolio Advisors, Inc 300 0
Putnam Investment Management, LLC 381471 0.63
Fidelity Management & Research Company LLC 3487318 5.79
First Trust Portfolios L.P. 10365 0.02
Columbia Wanger Asset Management LLC 541172 0.9
Baron Capital Management Inc 845643 1.4
Principal Global Investors, LLC 227853 0.38
Fidelity SelectCo, LLC 2635961 4.37
Granahan Investment Management Inc 91177 0.15
Kennedy Capital Management 41541 0.07
Westend Sa 1400000 2.32
AXA Investment Managers UK Ltd 207067 0.34
Invesco Capital Management LLC 67344 0.11
Zeus Asset Management S.A. 1253 0
Artal Group S A 1400000 2.32
BlackRock Fund Advisors 1270397 2.11
Artisan Partners Holdings LP 531970 0.88
Prudential Retirement Services 174917 0.29
PMG Fonds Management AG 17200 0.03

Содержится в ETF

ETF Доля, % Доходность за год, %
First Trust BuyWrite Income ETF 2.73
First Trust Hedged BuyWrite Income ETF 2.64

Похожие компании

Описание Acceleron Pharma Inc.

Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.